References
- Huillard O, Bakalian S, Levy C, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer Oxf Engl 1990. 2014;50(3):638–648. doi:10.1016/j.ejca.2013.10.016.
- Jenkins TL, Aderman CM, Ho AC. Reversible retinal toxicity in a patient taking axitinib. Retin Cases Brief Rep. 2021;15(3):239–242. doi:10.1097/ICB.0000000000000771.
- Kimura M, Kusuhara S, Tagami M, Nakamura M. Impaired retinal circulation during axitinib treatment for metastatic renal cell carcinoma. Case Rep Ophthalmol. 2019;10(1):5–10. doi:10.1159/000496197.
- Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients. Curr Oncol Rep. 2016;18(8):49. doi:10.1007/s11912-016-0536-7.
- Li ZY, Fan XX, Wang YJ, et al. Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib. Oncotarget. 2016;7(23):35181–35187. doi:10.18632/oncotarget.9285.
- Szczepanik S, Kęcik D. Bilateral central retinal vein occlusion in a patient with disseminated metastatic renal cell carcinoma treated with sorafenib. Retin Cases Brief Rep. 2012;6(2):148–150. doi:10.1097/ICB.0b013e3182160965.
- Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P. A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(5):758–768. doi:10.1016/j.jtho.2016.01.014.